The EU Ombudsman June 4 criticized the European Medicines Agency’s (EMA) lack of transparency and guidelines for deciding when to require drugmakers to carry out pediatric clinical trials.
EMA Chided Over Lack of Transparency in Pediatric Trials Waiver Process
- Post author:Sam
- Post published:April 8, 2016
- Post category:QMN Weekly Bulletin